1. Scrip

Novartis' Cosentyx Goes Head-To-Head With Humira

 
• By Kevin Grogan

With the initiation of EXCEED and SURPASS, Novartis is aiming to challenge Humira’s status as the preferred first-line biologic for ankylosing spondylitis and psoriatic arthritis.

Arm wrestling
Novartis challenging Humira's dominance in AS and PsA • Source: Shutterstock

Novartis AG has begun two head-to-head trials looking to show superiority of Cosentyx (secukinumab) over the world's biggest-selling drug – AbbVie Inc.'s Humira (adalimumab) – for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D